KDUS Cadus Corp. featured news, full reports, and detailed charts
Cadus Corp. (KDUS/KDUS.OB) Wrap Up:
Cadus Corporation focuses on licensing yeast-based drug discovery technologies. It licenses various reagents and its library of over 30,000 yeast strains, as well as bioinformatics software. The company, formerly known as Cadus Pharmaceutical Corporation, was founded in 1992 and is based in New York, New York.Founded in 1992
Cadus Corp. (KDUS:OTC Bulletin Board Market)
LAST $1.47 USD
CHANGE TODAY 0.00 0.00%
VOLUME 0.0
As of November 11, 2009 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Cadus Corp. (KDUS)
|
OPEN
--
|
PREVIOUS CLOSE
$1.47
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
10/6/09 - $1.60
|
52 WEEK LOW
11/21/08 - $1.16
|
|
|
MARKET CAP
19.3M
|
AVERAGE VOLUME 3 mo
110.0
|
|
|
DILUTED EPS TTM
$-0.10
|
SHARES OUTSTANDING
13.1M
|
|
|
KDUS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
KDUS Top Compensated Officers
Mr. David Blitz
Acting Chief Executive Officer, Acting Presid...
Age: 77
Total Annual Compensation: $25.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Cadus Corp. (KDUS)
Cadus Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/16/2009
Cadus Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company's revenues were $0 for the third quarter of 2009 and for the same period in 2008. Income before provision for income taxes and net income was $18,251, compared to loss before provision for income taxes and net loss of $110,944 for the same period in 2008. Basic net income per share was $0.00 compared to basic net loss per share of $0.01 for the same period in 2008. Operating loss was $132,110 compared to $138,276 for the same quarter a year ago. For the nine months, the company's revenues were $100,000 for the first nine months of 2009 and for the same period in 2008. Net loss was $157,651 compared to a net loss of $266,145 for the same period in 2008. Basic net loss per share was $0.01, compared to a basic net loss per share of $0.02 for the same period in 2008. Operating loss was $380,619 compared to $423,568 for the same period a year ago. Loss before provision for income taxes was $157,651 compared to $264,487 for the same period a year ago.
Cadus Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2009
08/13/2009
Cadus Corp. reported earnings results for the second quarter and six months ended June 30, 2009. Revenues were $0 for the second quarter of 2009 and for the same period in 2008. Net loss for the second quarter of 2009 was $103,330, compared to net income of $52,795 for the same period in 2008. Basic net loss per share for the second quarter of 2009 was $0.01, compared to basic net income per share for the second quarter of 2008 of $0.00. The operating loss was $144,762 compared to $120,684 in the previous year period. Loss before provision for income taxes was $103,330 compared income before provision for income taxes to $54,453 in the previous year period. Revenues were $100,000 for the first six months of 2009 and for the same period in 2008. Net loss for the first six months of 2009 was $175,902, compared to a net loss of $155,201 for the same period in 2008. Basic net loss per share for the first six months of 2009 was $0.01, compared to a basic net loss per share for the same period in 2008 of $0.01. The operating loss was $248,509 compared to $285,292 in the previous year period. Loss before provision for income taxes was $175,902 compared loss before provision for income taxes to $153,543 in the previous year period.
Cadus Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2009
05/15/2009
Cadus Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2009. For the quarter, the company reported Revenue was $100,000, compared to revenue of $100,000 for the same period in 2008. Net loss decreased to $72,572, compared to a net loss of $207,996 for the same period in 2008. The decrease in net loss can be principally attributed to a decrease in general and administrative expenses of $62,809 and the 2008 loss on write down of securities of $279,906 offset by a decrease in interest income of $207,417. Basic and diluted net loss per share for the first quarter of 2009 was $0.01, compared to basic and diluted net loss per share for the first quarter of 2008 of $0.02. Loss before provision for income taxes was $72,572 compared to $207,996 for the first quarter of 2008. Operating loss was $103,747 against $164,608 a year ago.
KDUS Competitors
| Company | Last | Change | |
| No competitor information is available for KDUS. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | KDUS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 193.2x |
|
| Price/Book | 0.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
KDUS |
||
|
KDUS transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Cadus Corp.
More news for KDUS
Cadus Reports Third Quarter 2009 Results
NEW YORK, Nov. 16 /PRNewswire-FirstCall/ -- Cadus Corporation (OTC Bulletin Board: KDUS - News) announced today financial results for the third quarter ended September 30, 2009. Revenues were $0 for the third quarter of 2009 and for the same period in 2008. Net income for the third quarter of 2009 was $18,251, compared to a net loss of $110,944 for the same period in 2008. Basic net income per share was $0.00 for the third quarter of 2009, compared to basic net loss per share of $0.01 for the same period in 2008.Revenues were $100,000 for the first nine months of 2009 and for the same period in 2008. Net loss for the first nine months of 2009 was $157,651, compared to a net loss of $266,145 for the same period in 2008. Basic net loss per share for the first nine months of 2009 was $0.01, compared to a basic net loss per share of $0.02 for the same period in 2008.As of October 31, 2009, Cadus had 13,144,040 shares outstanding.This press release may contain forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's annual report on Form 10-K for the year ended December 31, 2008. These include risks and uncertainties relating to the company's ability to license its technologies to third parties, the company's capital needs and uncertainty of future funding, the company's history of operating losses, the unpredictability of ...Click here to read the whole Article (external link)
CADUS CORP Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview The Company was incorporated in 1992 and until July 30, 1999, devoted substantially all of its resources to the development and application of novel yeast-based and other drug discovery technologies. On July 30, 1999, the Company sold its drug discovery assets and ceased its internal drug discovery operations and research efforts for collaborative partners. At September 30, 2009, the Company had an accumulated deficit of approximately $34.9 million. The Company's losses resulted principally from costs incurred in connection with its research and development activities and from general and administrative costs associated with the Company's operations. These costs exceeded the Company's revenues and interest income. As a result of the sale of its drug discovery assets and the cessation of its internal drug discovery operations and research efforts for collaborative partners, the Company ceased to have research funding revenues and substantially reduced its operating expenses. The Company expects to generate revenues in the future only if it is able to license its technologies. Results of Operations Three Month Ended September 30, 2009 and 2008. Revenues There were no revenues for the three months ended September 30, 2009 and 2008. Costs and Expenses General and administrative expenses decreased to $110,646 for the three months ended September 30, 2009 from $118,421 for the same period in 2008. Professional fees decreased by $3,505 and other costs decreased by $4,270. For the three months ended September 30, 2009, the Company recognized $144 in its investment in Laurel Partners Limited Partnership. The income for the same period in 2008 was $1,753. Interest Income Interest income for the three months ended September 30, 2009 was $14,177 compared to interest income of $161,180 for...Click here to read the whole Article (external link)
CADUS CORP Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
CADUS CORP Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview The Company was incorporated in 1992 and until July 30, 1999, devoted substantially all of its resources to the development and application of novel yeast-based and other drug discovery technologies. On July 30, 1999, the Company sold its drug discovery assets and ceased its internal drug discovery operations and research efforts for collaborative partners. At June 30, 2009, the Company had an accumulated deficit of approximately $34.9 million. The Company's losses have resulted principally from costs incurred in connection with its research and development activities and from general and administrative costs associated with the Company's operations. These costs have exceeded the Company's revenues and interest income. As a result of the sale of its drug discovery assets and the cessation of its internal drug discovery operations and research efforts for collaborative partners, the Company ceased to have research funding revenues and substantially reduced its operating expenses. The Company expects to generate revenues in the future only if it is able to license its technologies. Results of Operations Three Month Ended June 30, 2009 and 2008. Revenues There were no revenues for the three months ended June 30, 2009 and 2008. Costs and Expenses General and administrative expenses increased to $123,153 for the three months ended June 30, 2009 from $100,877 for the same period in 2008. Patent costs decreased by $1,764, accounting and legal expenses increased by $1,232, and other costs increased by $22,808. For the three months ended June 30, 2009, the Company recognized no income in its investment in Laurel Partners Limited Partnership. The income for the same period in 2008 was $1,802. Interest Income Interest income for the three months ended June 30, 2009 was $22,162 compared t...Click here to read the whole Article (external link)
CADUS CORP Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview The Company was incorporated in 1992 and until July 30, 1999, devoted substantially all of its resources to the development and application of novel yeast-based and other drug discovery technologies. On July 30, 1999, the Company sold its drug discovery assets and ceased its internal drug discovery operations and research efforts for collaborative partners. At March 31 2009, the Company had an accumulated deficit of approximately $34.8 million. The Company's losses have resulted principally from costs incurred in connection with its research and development activities and from general and administrative costs associated with the Company's operations. These costs have exceeded the Company's revenues and interest income. As a result of the sale of its drug discovery assets and the cessation of its internal drug discovery operations and research efforts for collaborative partners, the Company ceased to have research funding revenues and substantially reduced its operating expenses. The Company expects to generate revenues in the future only if it is able to license its technologies. Results of Operations Three Month Ended March 31, 2009 and 2008. Revenues Revenues for the three months ended March 31, 2009 and 2008 were $100,000, which is the annual maintenance fee from OSI. Costs and Expenses General and administrative expenses decreased to $182,467 for the three months ended March 31, 2009 from $245,276 for the same period in 2008. Patent costs decreased by $19,340, accounting and legal expenses decreased by $27,416, consulting costs decreased by $8,987 due to the reduced cost in 2009 for an internal control consultant to conform with Section 404 of the Sarbanes-Oxley Act. There were net other decreases of $7,066. For the three months ended March 31, 2009, the Company recognized income of $328 in ...Click here to read the whole Article (external link)
CADUS CORP Files SEC form 10-K, Annual Report
Item 7. Management's Discussion and Analysis of Financial ConditionAnd Results Of Operations. Overview Cadus was incorporated in 1992 and until July 30, 1999, devoted substantially all of its resources to the development and application of novel yeast-based and other drug discovery technologies. On July 30, 1999, Cadus sold its drug discovery assets to OSI Pharmaceuticals, Inc. ("OSI") and ceased its internal drug discovery operations and research efforts for collaborative partners. Cadus currently has limited operations, no employees and the Company's current Chief Executive Officer is a consultant. See Item 10. Directors and Officers of the Company. The Company is currently seeking to (i) license the Subsidiary's drug discovery technologies and (ii) to use a portion of its available cash to acquire or invest in companies or income producing assets. While such companies or assets might be in the biotechnology or pharmaceutical industries, the Company will consider acquisitions or investments in other industries as well. The Company has incurred operating losses in each year since its inception except for an operating gain of approximately $214,000 for the year ended December 31, 2002. At December 31, 2008, the Company had an accumulated deficit of approximately $34.7 million. The Company's losses have resulted principally from costs incurred in connection with its research and development activities and from general and administrative costs associated with the Company's operations. These costs have exceeded the Company's revenues and interest income. As a result of the sale of its drug discovery assets to OSI and the cessation of its internal drug discovery operations and research efforts for collaborative partners, the Company ceased to have research funding revenues and substantially reduced its operating expenses. Despite the fact that the Company has no employees and limited operations, it continues to incur general and administrative expenses. ...Click here to read the whole Article (external link)
CADUS CORP Files SEC form 10-Q, Quarterly Report
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview The Company was incorporated in 1992 and until July 30, 1999, devoted substantially all of its resources to the development and application of novel yeast-based and other drug discovery technologies. On July 30, 1999, the Company sold its drug discovery assets and ceased its internal drug discovery operations and research efforts for collaborative partners. At September 30, 2008, the Company had an accumulated deficit of approximately $33.7 million. The Company's losses have resulted principally from costs incurred in connection with its research and development activities and from general and administrative costs associated with the Company's operations. These costs have exceeded the Company's revenues and interest income. As a result of the sale of its drug discovery assets and the cessation of its internal drug discovery operations and research efforts for collaborative partners, the Company ceased to have research funding revenues and substantially reduced its operating expenses. The Company expects to generate revenues in the future only if it is able to license its technologies. Results of Operations Three Month Ended September 30, 2008 and September 30, 2007 Revenues There were no revenues for the three months ended September 30, 2008 and 2007. Costs and Expenses General and administrative expenses increased to $118,421 for the three months ended September 30, 2008 from $82,208 for the same period in 2007. Patent costs increased by $9,953, accounting and legal expenses increased by $22,888, and shareholder relations increased by $1,520. There were other increases of $1,852. For the three months ended September 30, 2008 the Company recognized income of $1,753 in its investment in Laurel Partners Limited Partnership. Such income for the same period in 2007 was $3,919. Interest Inco...Click here to read the whole Article (external link)
Would you like to leave a comment about Cadus Corp. KDUS/KDUS.OB
Find out what social network information about Cadus Corp. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Cadus Corp. there is more great information available at Realpennies.com